The FDA has approved a new drug from Pfizer for lung-cancer patients with a particular genetic mutation.
Pfizer’s drug Xalkori blocks proteins produced by an abnormal gene that causes tumor growth in up to about 7 percent of patients with non-small-cell lung cancer.